Treats Duchenne muscular dystrophy (DMD). Sold as Viltepso. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Viltolarsen (sold as Viltepso), first approved Aug 12, 2020, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Viltepso | Part D | $4.9M | +12% | 0 |
| Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)Duchenne Muscular Dystrophy · NS Pharma, Inc. | Phase 3 | Active, not recruiting | Feb 24, 2021 |
| Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)Duchenne Muscular Dystrophy · NS Pharma, Inc. | Phase 4 | Active, not recruiting | Dec 29, 2020 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Aug 12, 2020 | ViltepsoNDA 212154 · New molecular entity | Nippon Shinyaku | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA